Durvalumab plus radiotherapy after first treatment for limited lung spread
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This phase 2 trial studies whether durvalumab given with consolidation radiotherapy can help people with extensive-stage small cell lung cancer that has only a few metastases. It builds on initial chemotherapy and immunotherapy response, then targets the chest and limited metastatic spots with radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed small cell lung cancer from biopsy (tissue) or fluid (cytology).
- Your scan shows fewer than 5 metastatic spots (oligometastatic disease).
- You finished 4 to 6 cycles of durvalumab plus standard chemotherapy (platinum plus etoposide), and your cancer responded well (complete or partial response).
- A radiation specialist believes your chest and the limited metastatic areas can be treated with radiotherapy.
- You are 18 to 70 years old, and your energy/fitness score is 0 to 1.
- Your blood counts, liver and kidney tests are strong enough, and you are expected to live at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.